Over 72 mutations have been identified in the HEXA gene of which only four (T538C, A590C, G805A, and C1495T) are believed to cause a chronic form of Tay-Sachs disease (TSD). We identified a novel HEXA mutation (IVS7, -7 G→A) leading to chronic TSD in a Canadian patient of English ancestry. The second allele in this patient was the exon 11 4-bp insertion mutation (▼1277TATC), which is the most frequent TSD allele in Ashkenazi Jews. The IVS7, -7 G→A mutation introduces a new 3' splice acceptor site 5 bp upstream of the normal intron 7 splice acceptor site. The mutation leads to reduction of steady-state levels of HEXA mRNA by more than 80%. Two mRNA species are produced by the IVS7, -7 G→A allele; a normal nRNA species and an mRNA lacking exon 8. No mRNA species that was spliced at the upstream 3' splice acceptor site was detected. We used competitive PCR to quantitate mRNA species in fibroblasts obtained from this patient. We compared the amounts of three identified mRNA species to HEXA mRNA levels in cells from normal individuals and from individuals heterozygous for ▼1277TATC. The steady-state level of HEXA mRNA in cells from a normal individual was 17.3 pg/pg RNA. An individual heterozygous for ▼1277TATC produced 8.7 pg of normal HEXA mRNA/pg RNA. The HEXA mRNA species with the insertion mutation was present in patient cells at 4.8% of the level of normal HEXA nRNA in homozygous normal cells. In fibroblasts from the patient carrying the IVS7, -7 G→A mutation, the steady-state level of exon 8-deleted HEXA mRNA was 5.9% the level of that produced by homozygous normal cells. The level of normal HEXA nRNA in this patient’s cells was 10.4%.

Keywords:
Chronic variant GM(2) gangliosidosis, Splicing defects, mRNA quantitation
This content is only available via PDF.
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.